Clinical Trial

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Study acronym: ECLYPse
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-10.
Trial Details
NCT Number NCT06640166
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: Pierre Fabre Pharma GmbH
Conditions Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma +2 more
Enrollment 25 participants
Start Date 2024-06-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-12